{"filings":[{"id":1637399,"accession_number":"0001193125-26-303190","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-07-14T20:15:12+00:00","items":["1.01","9.01"],"status":"ready","headline":"Jaguar Health subsidiary Napo enters new 3-year manufacturing agreement with Alivus for crofelemer supply","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New agreement with Alivus Life Sciences for manufacture of crofelemer for Mytesi and other products.","Term from July 9, 2026 to March 31, 2029; replaces prior agreement that expired March 31, 2026.","Includes minimum purchase quantities; shortfall payment obligation if not met.","May be terminated for any reason with 12 months' notice, or for material breach with 90-day cure.","In insolvency, rights assigned to Woodward Specialty LLC (affiliate of Future Pak)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1388836,"accession_number":"0001193125-26-292677","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-07-01T20:34:03+00:00","items":["8.01"],"status":"ready","headline":"Jaguar Health completes conversion of Series O Preferred Stock; shares outstanding now 4.86M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On June 25, 2026, all outstanding Series O Preferred Stock and shares issuable upon Eligible Warrants converted into common stock at 3.209:1 ratio.","Immediately after conversion, common shares outstanding totaled 4,857,211.","Eligible Warrants holders can receive up to 839,000 additional common shares upon exercise.","The Series O Preferred Stock was originally issued as a special one-time dividend on March 4, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1260237,"accession_number":"0001193125-26-281969","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-06-25T13:15:57+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Jaguar Health converts Series O Preferred Stock to common at 3.209:1, pays $2.68 for fractions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Each share of Series O Preferred Stock converted into 3.209 common shares on June 25, 2026; fractional shares paid in cash at $2.68/share.","Preferred stock was issued as a one-time stock dividend to common stockholders and warrant holders of record March 2, 2026.","Company targeting Breakthrough Therapy designation for crofelemer in MVID with NDA filing planned for H1 2027.","Initial MVID patient in proof-of-concept trial showed up to 37% reduction in parenteral support needs; data presented at ESPGHAN June 2026.","First Amendment to supply agreement with Woodward clarifies inventory title transfer and transition period through Dec 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1195556,"accession_number":"0001193125-26-277570","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K/A","filed_at":"2026-06-22T20:25:36+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jaguar Health explores strategic alternatives for crofelemer rare disease program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board initiates process to explore strategic alternatives including M&A, partnerships, licensing; no guarantee of transaction.","Timing aligns with planned NDA filing for crofelemer in rare intestinal failure diseases (MVID, SBS-IF).","Proof-of-concept trial in MVID/SBS-IF showed up to 37% reduction in parenteral support.","Market research estimates global nutritional support for MVID at ~$1.1B in 2026, rising to ~$1.5B in 2033.","CEO Lisa Conte to present updates at Life Sciences Virtual Investor Forum on June 24, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1178436,"accession_number":"0001193125-26-276845","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-06-22T13:17:24+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jaguar Health explores strategic alternatives; crofelemer NDA targeted for rare intestinal failure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board initiated process to evaluate strategic alternatives including M&A, partnerships, and licensing to maximize shareholder value.","Process aligns with planned completion of clinical work for NDA submission for crofelemer in rare intestinal failure diseases.","Crofelemer reduced parenteral support by up to 37% in pediatric MVID/short bowel syndrome proof-of-concept trial.","Third-party report estimates global nutritional support market for MVID at ~$1.1B in 2026, growing to ~$1.5B by 2033.","CEO Lisa Conte to update on crofelemer program at Life Sciences Virtual Investor Forum on June 24, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1140800,"accession_number":"0001193125-26-276103","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-06-18T21:16:09+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Jaguar Health amends royalty agreements to $750k minimum, extends Streeterville debt, exchanges preferred for common","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Royalty amendments: Uptown and Streeterville minimum monthly payment increased to $750k, effective Oct 1, 2026.","Streeterville royalty payment start extended from July 1 to Oct 1, 2026; $6.22M note maturity also extended to Oct 1, 2026.","Exchanged 10.88 shares of Series Q Preferred for 110,249 common shares (three deals June 9, 17, 18).","Aggregate common stock issuance exceeded 5% of outstanding; shares free-trading without legend under Section 3(a)(9)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":982916,"accession_number":"0001193125-26-266770","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-06-11T13:00:07+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Jaguar Health secures up to $40M equity line and $2M preferred stock financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ELOC agreement provides up to $40M of common stock purchases; floor price set at $1.10 per share.","Single fixed purchase capped at $1.5M; $800K commitment shares to be issued upon registration effectiveness.","Series P preferred stock financing: 240 shares at $10K stated value, 8% annual dividend, mandatory redemption with ELOC proceeds.","Stockholder approval obtained June 8, 2026 allowing issuances beyond 19.99% for both facilities.","Proceeds intended for general corporate purposes; registration statements to be filed within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":919516,"accession_number":"0001193125-26-261910","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-06-08T20:41:08+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Jaguar Health stockholders approve all five proposals, including share issuances up to >19.99% to C/M Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["John Micek III elected Class II director with 3,967,085 for, 240,944 withheld.","Ratification of RBSM LLP as auditor approved: 6,898,326 for.","Proposal 3 (ELOC Agreement with C/M Capital) approved: 3,891,273 for, 291,441 against.","Proposal 4 (Preferred Stock Purchase Agreement with C/M Capital, including Series P Preferred) approved: 3,846,847 for.","Proposal 5 (adjournment authority) approved: 3,928,027 for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":805998,"accession_number":"0001193125-26-253506","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-06-02T20:10:13+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Jaguar Health issues 64,668 common shares for Series Q Preferred; annual meeting adjourned to June 8","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 31,958 and 32,710 common shares to Streeterville on May 26 and June 1, 2026, respectively, in exchange for 3.72 and 4.2 Series Q Preferred shares.","Shares issued under Section 3(a)(9) exemption; no cash consideration exchanged.","Annual meeting reconvened June 2 but further adjourned to June 8 for stockholders to review proxy supplement filed May 29.","Record date remains April 15; stockholders who already voted need not take further action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":678637,"accession_number":"0001193125-26-240645","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-05-27T13:10:06+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Formal notice from Nasdaq on May 26, 2026: Jaguar complies with Bid Price Rule (closing bid ≥$1/sh).","Panel maintains jurisdiction until Sept 1, 2026; Mandatory Panel Monitor imposed until May 26, 2027.","If bid price <$1 for 30 consecutive trading days during monitoring, no 180-day grace period; delisting possible.","CEO Lisa Conte reported Q1 2026 net revenue +816% YoY and +527% QoQ, driven by out-license with Future Pak.","Company targets NDA for crofelemer formulation in mid-2027 and seeks development/commercialization partner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":611958,"accession_number":"0001193125-26-237195","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-05-22T21:22:44+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Jaguar Health issues 54k shares to Streeterville in exchange for Series Q preferred; adjourns annual meeting to June 2","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 54,222 common shares to Streeterville in exchange for 7.96 shares of Series Q Preferred Stock.","Common shares to be issued without restrictive legend; Streeterville can resell under Rule 144 using tacked holding period from Aug 2022.","Annual Meeting adjourned to June 2, 2026; supplement to proxy to be filed after discussions with Nasdaq staff.","Company plans to provide additional information to stockholders regarding certain proposals in the proxy statement.","Record date remains April 15, 2026 for the reconvened meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":555516,"accession_number":"0001193125-26-232722","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-05-20T20:36:22+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jaguar Health Q1 revenue up 816% to $20.3M on $19M license deal; net loss narrows to $7.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $20.3M (816% YoY increase) driven by $19.1M license revenue from Woodward/Future Pak deal.","Product revenue $1.2M, down 45% YoY; Mytesi/Canalevia-CA1 rights licensed to Future Pak in Jan 2026.","Net loss attributable to common stockholders $7.0M, improved 33% from $10.5M loss in Q1 2025.","Non-GAAP recurring EBITDA loss $5.1M, improved 48% from $9.7M loss a year ago.","Company to present crofelemer data for rare-disease intestinal failure at ESPGHAN June 2026."],"consensus_eps_estimate":-2.0808,"consensus_eps_actual":-13.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":20272000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":528996,"accession_number":"0001193125-26-231083","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-05-19T21:07:21+00:00","items":["1.01","2.03","3.02","5.03","9.01"],"status":"ready","headline":"Jaguar Health exchanges $22.7M in royalty interests for Series Q Preferred Stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Uptown Capital: $12.5M royalty reduction for 500 Series Q shares.","Streeterville: $3.7M reduction (148 shares) + $6.5M reduction (260 shares).","Series Q carries 10% annual preferred return payable in additional Series Q shares.","Company can exchange Series Q for common at Minimum Price; 9.99% ownership cap.","Restrictive covenants include equity issuance limit and majority-holder consent rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93885,"accession_number":"0001193125-26-211545","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Jaguar Health gets Nasdaq extension to May 18 for bid-price compliance; delisting risk remains","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Staff notice on May 1, 2026 for non-compliance with 500,000 publicly held shares requirement.","Investors exercised pre-funded warrants on May 4, 2026, curing publicly held shares deficiency.","Panel granted one-day extension to May 18, 2026 to show closing bid price >= $1.00 for 10 consecutive days.","Company warns it may not meet the extension terms and could face delisting from Nasdaq.","Non-compliance with bid price rule clock reset after cure of publicly held shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93884,"accession_number":"0001193125-26-204310","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Jaguar Health cures Nasdaq publicly held shares deficiency via warrant exercises after reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on May 1, 2026 for non-compliance with minimum 500,000 publicly held shares after 1-for-35 reverse split on April 30.","Post-split publicly held shares were ~401,226, below the 500,000 requirement.","On May 4, 2026, warrant exercises increased publicly held shares to 513,939.","Company now has 513,974 total shares outstanding; awaiting Nasdaq formal confirmation of compliance.","Reverse split had also triggered continued non-compliance with bid price rule until cure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93883,"accession_number":"0001193125-26-202614","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Jaguar Health receives Nasdaq delisting notice for insufficient publicly held shares after reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Post 1-for-35 reverse stock split on April 30, 2026, publicly held shares are ~401,226, below 500,000 minimum.","Nasdaq Staff notified company on May 1, 2026 of additional deficiency under Listing Rule 5550(a)(4).","Company must present views to Nasdaq Hearings Panel by May 8, 2026; failure may lead to delisting.","Company remains non-compliant with both minimum bid price and public shares requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93882,"accession_number":"0001193125-26-179391","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["3.01","3.03","5.03","7.01","9.01"],"status":"ready","headline":"Jaguar Health granted Nasdaq extension to May 15, 2026; announces 1-for-35 reverse stock split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Panel grants extension until May 15, 2026 to demonstrate compliance with $1.00 minimum bid price rule.","Company must close at $1.00+ for at least 10 consecutive business days by May 15.","Reverse stock split at 1-for-35 effective April 30, 2026; trading continues on Nasdaq under JAGX.","Reverse split approved at April 20, 2026 special meeting; no fractional shares – cash in lieu.","Panel retains jurisdiction until September 1, 2026; delisting risk persists if compliance not met."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93881,"accession_number":"0001193125-26-165120","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["5.03","5.07","7.01","9.01"],"status":"ready","headline":"Jaguar Health stockholders approve authorized share increase and two reverse stock split proposals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 298M to 500M shares; total authorized shares from 352M to 554M.","Two reverse stock split proposals approved, each at board-chosen ratio between 1:15 and 1:150.","Issuance of up to $10.81M in shares upon exchange of secured promissory note to Streeterville Capital approved.","All five proposals passed with significant majority; Proposal 1 received 6,031,263 For votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93880,"accession_number":"0001193125-26-149828","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Jaguar Health regains Nasdaq equity compliance after $27M in capital events","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' deficit was $18.7M at Dec 31, 2025, below Nasdaq's $2.5M minimum.","Received $16M license fee, $3M buy-back termination, $1M inventory purchase from Woodward/Future Pak.","Also received $2M MSA condition payment, $1.2M firm order, grant revenue, and $0.2M net sales.","Gain of $3.4M on debt extinguishment to Chicago Venture Partners helped restore equity.","Company believes stockholders' equity exceeded $2.5M as of April 7, 2026, curing the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93879,"accession_number":"0001193125-26-144604","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jaguar Health FY2025 net loss widens to $53.6M; enters Future Pak deal for non-dilutive capital; Nasdaq appeal pending","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue FY2025 $11.5M (-1.5% YoY); Q4 2025 net revenue $3.2M (+5% QoQ, -8% YoY).","Net loss attributable to common stockholders FY2025 $53.6M vs $38.5M; loss from operations $45.9M.","Mytesi prescription volume down 3.7% in 2025 vs 2024; Q4 2025 down 12.2% YoY.","Entered license agreement with Future Pak Jan 2026: $16M up-front non-dilutive capital, $2M additional upon conditions; FP to commercialize Mytesi and Canalevia-CA1.","Received Nasdaq noncompliance notice; appeal hearing April 7, 2026; delisting stayed pending decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105860,"accession_number":"0001193125-26-097700","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Jaguar Health postpones royalty payments, extends notes, terminates 48,211 warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Royalty payment start postponed to July 1, 2026; Uptown amount reduced to $11,125,282.54, Streeterville to $12,428,782.20.","2021 Note maturity extended to July 1, 2026; Outstanding Balance reduced to $6,596,304.11.","2025 Note maturity extended to March 12, 2029; Outstanding Balance reduced to $7,048,021.86.","Warrants for 48,211 shares of common stock terminated via agreement with Uptown, Streeterville, and Iliad.","Napo granted Streeterville security interest in Lechlemer and TDPRV collateral to secure 2025 Note."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105859,"accession_number":"0001193125-26-096565","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Jaguar Health receives Nasdaq delisting notice for bid price; plans to appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice on March 5, 2026: bid price below $1.00 for 30 consecutive business days.","Company ineligible for compliance period due to reverse stock split(s) in prior two years.","Must request appeal by March 12, 2026; intent to timely appeal to Hearings Panel.","Appeal request automatically stays suspension pending hearing outcome; no guarantee of relisting.","Ticker JAGX trades on Nasdaq; delisting would occur if appeal fails."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105858,"accession_number":"0001193125-26-086882","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Jaguar Health files Series O Preferred Stock certificate for special dividend payable March 4","summary_kind":"llm","event_type":"dividend","confidence":"medium","bullets":["Filed Certificate of Designation for 1,557,000 shares of Series O Convertible Preferred Stock.","Special dividend of 1/10th Series O share per common share + each of 2,400,765 eligible warrant shares; record date March 2.","Series O has no dividends, limited voting rights, liquidation preference $0.0001/share, and conversion at Minimum Price by Dec 31, 2026.","Transfer restricted without company consent; conversion limited to 19.99% beneficial ownership cap.","No trading market for Series O; optional conversion by company or automatic conversion on Dec 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105857,"accession_number":"0001193125-26-056157","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["3.03","8.01","7.01","9.01"],"status":"ready","headline":"Jaguar Health Declares Special Stock Dividend to Provide Dilution Protection as It Explores Debt Restructuring","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Jaguar Health declared a one-time special stock dividend of Series O Preferred Stock on February 18, 2026.","Record date is March 2, 2026; payment date March 4. Each common share receives 0.1 Series O share.","Dividend aims to protect shareholders from dilution as Jaguar explores debt restructuring pathways.","Series O Preferred Stock is non-transferable, has no trading market, and will automatically convert by Dec 31, 2026.","Full conversion at assumed $0.40 price would issue 20.99M shares, diluting non-participating stockholders by 60.65%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105856,"accession_number":"0001193125-26-021064","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Jaguar Health issues ~11.8M pre-funded warrants to reduce $2.04M in royalties and preferred stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduced $1.19M Iliad royalty and $0.85M Streeterville royalty by issuing 1.55M and 1.11M pre-funded warrants.","Exchanged 22 Series L preferred shares (Iliad) and 99.38 shares (Streeterville) for 0.72M and 3.25M pre-funded warrants.","Exchanged 87.78 Series M shares (Iliad) and 69.44 shares (Streeterville) for 2.87M and 2.27M pre-funded warrants.","Warrants exercisable immediately at $0.001/share; no cash received in the exchanges."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105855,"accession_number":"0001193125-26-014231","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive license to Future Pak for Mytesi (HIV/AIDS diarrhea) and Canalevia-CA1 (chemotherapy-induced diarrhea in dogs) in U.S.","Jaguar receives $18M upfront ($16M at closing + $2M on conditions) and up to $20M in milestone/future payments.","Jaguar retains manufacturing role; non-dilutive capital funds rare-disease pipeline (short bowel syndrome, MVID).","Jaguar has buy-back option after 5 years or upon FDA approval of additional crofelemer indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105854,"accession_number":"0001193125-26-009644","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Jaguar Health closes $350K private placement of 6% notes and warrants for working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $350K aggregate principal of 6% unsecured promissory notes to accredited investors on Jan 6, 2026.","Notes mature one month from issuance; prepayable without penalty.","Investors received warrants to purchase up to 350K shares at $1.00/share, exercisable for 5 years.","Proceeds used for working capital and general corporate purposes.","Amendment corrects execution and closing dates in original 8-K from Jan 6 to Jan 6 (scrivener's error)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105853,"accession_number":"0001193125-26-009221","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Jaguar Health issues $350K in 6% notes and warrants for 350K shares at $1.00","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $350,000 aggregate principal amount of unsecured promissory notes to two accredited investors.","Notes bear 6% annual interest and mature one month from issuance; prepayable without penalty.","Investors received warrants to purchase up to 350,000 shares of common stock at $1.00/share, exercisable immediately for five years.","Proceeds used for working capital and general corporate purposes; transaction closed January 5, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105852,"accession_number":"0001193125-26-010173","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K/A","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Jaguar Health issues $350K in 6% notes with warrants; corrects prior filing dates","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $350,000 aggregate principal amount of 6% unsecured promissory notes to two accredited investors.","Warrants to purchase up to 350,000 shares at $1.00 per share, exercisable immediately, expire in 5 years.","Proceeds used for working capital and general corporate purposes; transaction closed on January 6, 2026.","This 8-K/A corrects scrivener's errors in the original filing regarding execution and closing dates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122122,"accession_number":"0001193125-25-317693","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Jaguar Health swaps 91 Series M Preferred shares for 440K common shares and 1.6M pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Dec 9, exchanged 75 Series M Preferred for 400K common shares and warrant for 1,304,545 shares at $0.001.","On Dec 11, exchanged 16 Series M Preferred for 40K common shares and warrant for 304,827 shares at $0.001.","Total 91 Series M Preferred shares cancelled; pre-funded warrants exercisable immediately with 9.99% beneficial ownership blocker.","Transaction executed with Iliad Research and Trading, L.P. via private exchange agreements under Section 3(a)(9).","Issuance reduces preferred liquidation preference; adds ~2.05M fully diluted shares to existing common."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122121,"accession_number":"0001193125-25-311294","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"JAGX stockholders approve three proposals; crofelemer MVID trial shows up to 37% PS reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved proposal to issue shares upon exchange/redemption of Series N Preferred Stock (1,032,716 For, 73,065 Against).","Stockholders approved proposal to issue New PIPE Shares and Pre-Funded Warrant under Sept 28 securities purchase agreement (2,049,724 For).","Stockholders approved adjournment proposal (2,058,277 For).","Initial MVID proof-of-concept trial shows crofelemer can reduce total parenteral support by up to 37% in infants with microvillus inclusion disease.","Company met with FDA on Oct 2, 2025 for advice on expedited approval pathway for crofelemer for MVID; no approved treatments exist."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122120,"accession_number":"0001193125-25-287650","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Jaguar Health amends $36M royalty obligations, extends debt, exchanges preferred for common","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Royalty Interest amendments set minimum monthly payment of $750,000 per $12M royalty from April 1, 2026.","Note Amendment No. 2 extends maturity of $6.22M secured promissory note to April 1, 2026.","Exchange of 25 Series M Preferred shares for 361,271 common shares; issued unregistered under Section 3(a)(9)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122119,"accession_number":"0001193125-25-283139","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Jaguar Health issues $10.81M secured note to Streeterville Capital; $8M held as collateral","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Net proceeds of $10M after $800K OID and $10K transaction expenses; interest 8% p.a., maturity 36 months.","$8M deposited in restricted account at Lakeside Bank as collateral; release allowed for excess over declining requirement.","Lender can redeem up to $600K/month starting month 12; mandatory prepayment of 25% of upfront IP licensing fees.","Note secured by subsidiary guaranty (JAGX Holdings) and pledge of all its membership interests; strict negative covenants on additional debt and equity.","Proceeds at Company's discretion, including repayment of $6M June 2025 convertible bridge notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122118,"accession_number":"0001193125-25-230298","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Jaguar Health issues 286,532 shares to reduce royalty interest by $600,000","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued 286,532 common shares in exchange for $600,000 reduction in outstanding royalty interest balance.","Exchange agreement entered September 30, 2025 with a holder of royalty interest.","Shares issued under Section 3(a)(9) exemption from registration; form of agreement incorporated by reference.","Transaction reduces debt-like royalty obligation without cash outlay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122117,"accession_number":"0001193125-25-226788","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Jaguar Health raises $1M via PIPE: 161,583 shares + 479,442 pre-funded warrants at $1.56/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 161,583 common shares and 479,442 pre-funded warrants to Brown Stone Capital at $1.56/share (warrant price $1.5599); total proceeds $1M.","Proceeds to be used for working capital, general corporate purposes, and repayment of existing convertible notes.","Pre-funded warrants exercisable immediately after closing, subject to standard anti-dilution adjustments.","Company committed to file resale registration statement on Form S-3 by October 9, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138846,"accession_number":"0001193125-25-201351","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Jaguar Health raises $2.38M via Series N Perpetual Preferred Stock PIPE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued ~951 Series N Preferred shares at $2,500 stated value each for aggregate proceeds of $2.38M.","Series N Preferred non-dividend, non-convertible but exchangeable into common at $1.20 per share after shareholder approval.","Proceeds to be used for working capital and repayment of certain existing notes.","Company must seek stockholder approval within 90 days; beneficial ownership capped at 19.99%.","Registration statement for resale of exchange shares required within 30 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138845,"accession_number":"0001193125-25-183449","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Jaguar Health: Crofelemer cuts TPN needs in MVID/SBS; FDA outlines sNDA path for breast cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 7 proposals approved at Aug 19 annual meeting; directors elected, stock plan amended, share issuances authorized.","Initial proof-of-concept data: crofelemer reduced TPN up to 27% in MVID patient and up to 12.5% in SBS-IF patient.","FDA meeting aligned on regulatory pathway to complete supplemental NDA for crofelemer in metastatic breast cancer (orphan population).","Company plans to seek license partnerships for orphan indications to generate non-dilutive funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138844,"accession_number":"0001193125-25-180438","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Jaguar Health extends ATM manager Lucid's term to Dec 31, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sixth ATM Amendment extends Lucid Capital Markets' service as manager from June 30 to Dec 31, 2025.","After Dec 31, 2025, Ladenburg Thalmann becomes sole manager unless further extended.","Company filed a prospectus supplement and reimburses Ladenburg $2,500 for legal fees.","No other changes to the existing ATM agreement; all other terms remain in effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156328,"accession_number":"0001193125-25-152345","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["1.01","2.03","3.02","5.03","9.01"],"status":"ready","headline":"Jaguar Health cuts royalty debt by $6.5M, issues Series M preferred to Iliad and Streeterville","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 170 shares of Series M Preferred to Iliad for $4.25M reduction in October 2020 royalty interest.","Issued 90 shares of Series M Preferred to Streeterville for $2.25M reduction in August 2022 royalty interest.","Series M Preferred has $25,000 stated value, no dividends, and accrues a preferred return (10%-6% declining).","Company may exchange Series M shares for common stock at the lower of closing or 5-day average price.","Preferred holders gain consent rights over equity issuances, asset sales, and reverse splits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156327,"accession_number":"0001193125-25-145742","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Jaguar Health extends $2.57M convertible note maturity to Jan 30, 2026; issues new warrants at $2.70 strike","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Company entered Exchange Agreements with certain investors to replace ~$2.57M of 6% convertible notes originally due June 30, 2025; new maturity January 30, 2026.","Replacement Notes convertible at $5.535/sh (non-insider) or $5.555/sh (insider); New Warrants exercisable at $2.70/sh, expire in 18 months.","Insiders including CEO and board members participated in exchange, acquiring $492,012 principal of Replacement Notes and warrants for 177,138 shares.","Prior to extension, five investors converted $0.866M of original notes into equity.","Net proceeds from equity/debt financings or licensing above $8M must be used to repay Replacement Notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156326,"accession_number":"0001193125-25-124500","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Jaguar Health raises ~$1.5M in registered direct offering with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 246,306 shares at $6.09/share; gross proceeds ~$1.5M.","Concurrent private placement of warrants to buy up to 492,612 shares at $5.84, expiring in 24 months.","H.C. Wainwright serves as placement agent; fees: 7% cash, 6% warrant coverage (14,778 warrants at $7.6125).","Net proceeds for working capital, operating expenses, and repayment of outstanding convertible notes.","Closing expected May 22, 2025; shares offered under effective S-3 shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156325,"accession_number":"0001193125-25-120763","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["1.01","2.02","2.03","3.02","5.03","9.01"],"status":"ready","headline":"Jaguar Health reduces royalty debt by $1.016M via equity exchanges; Q1 results released","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Issued 60,000 shares to Iliad for $466,200 reduction in October 2020 royalty interest.","Exchanged all 99.3822 Series J shares for Series L perpetual preferred stock with Streeterville.","Issued 22 Series L shares to Iliad for $550,000 royalty reduction; Series L pays 0%/10%/15% preferred return.","Q1 2025 earnings press released (financial details not provided in filing).","Company will seek stockholder approval to exceed Nasdaq exchange cap for Series L conversions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156324,"accession_number":"0001193125-25-116385","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jaguar Health posts investor presentation on website; no specific content disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Slide presentation made available on May 9, 2025 under Item 7.01.","Exhibit 99.1 references a May 2025 investor presentation but no detailed figures or strategy are provided.","Filing lacks specific financial or operational updates beyond the presentation's availability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156323,"accession_number":"0001193125-25-111996","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Jaguar Health obtains waiver from noteholders to resume ATM stock sales","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Investors holding majority of $3.4M convertible notes waived VRT restriction.","Company may now issue common stock through ATM program with Ladenburg Thalmann & Lucid Capital.","Waiver effective May 5, 2025, signed by majority of noteholders.","Restriction remains in place for all other variable rate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156322,"accession_number":"0001193125-25-111691","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Jaguar Health issues 57,500 shares to reduce royalty interest by $632,500","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On April 30, 2025, issued 57,500 shares to a royalty interest holder in exchange for $632,500 reduction in outstanding balance.","Shares issued in reliance on Section 3(a)(9) exemption from registration under the Securities Act of 1933.","Transaction reduces the company's royalty obligation by exchanging equity for debt, with no cash proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156321,"accession_number":"0001193125-25-105825","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Crofelemer reduces TPN up to 27% in MVID and 12.5% in SBS-IF in proof-of-concept trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial POC data shows novel liquid crofelemer reduced parenteral support in MVID and SBS-IF patients by up to 27% and 12.5% respectively.","Data presented at ELITE PED-GI Congress; stool volume/frequency reduced and urine output increased, indicating improved oral absorption.","No approved drugs exist for MVID; crofelemer may qualify for EMA PRIME and FDA Breakthrough Therapy programs.","Company supports three investigator-initiated trials and two placebo-controlled Phase 2 studies for MVID/SBS-IF globally.","Additional POC results from IITs expected throughout 2025; early patient access possible in certain EU countries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156320,"accession_number":"0000950170-25-058973","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jaguar Health to discuss initial crofelemer POC results for MVID and SBS-IF on April 30 webcast","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Data presented April 26 at ELITE PED-GI Congress by Dr. Mohamad Miqdady.","No approved drug treatments for MVID, an ultrarare pediatric disease.","Webcast on April 30, 2025 at 8:30 AM ET; includes KOL commentary.","Ongoing POC IITs (3) and Phase 2 studies (2) for crofelemer in MVID and SBS-IF.","Possible expedited regulatory pathways for crofelemer in MVID discussed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156319,"accession_number":"0000950170-25-058627","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jaguar Health files updated investor presentation for Ped-GI congress; no detailed data","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO references updated investor presentation at 11th Annual Elite Ped-GI Congress 2025 in Abu Dhabi.","Exhibit 99.1 dated April 2025 provides only presentation title slide; no financial or pipeline specifics.","No new guidance, revenue figures, or clinical milestones disclosed in the filing.","Presentation is furnished under Item 7.01 and not filed for SEC liability purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156316,"accession_number":"0000950170-25-058837","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K/A","filed_at":"2025-04-25T23:59:59+00:00","items":["3.02","1.01","2.03","9.01"],"status":"ready","headline":"Jaguar Health extends note maturity to July 2025, reduces royalty balance by $1.09M via stock","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued 1,290,000 shares to a royalty holder in exchange for $1,094,952 reduction in outstanding royalty balance.","Entered Note Amendment with Streeterville Capital extending $6,220,812.50 secured promissory note maturity to July 20, 2025.","Note Amendment dated January 29, 2025, includes wholly-owned subsidiary Napo Pharmaceuticals as co-borrower.","Shares issued in the exchange rely on Section 3(a)(9) exemption from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156318,"accession_number":"0000950170-25-055951","cik":1585608,"company_name":"Jaguar Health, Inc.","ticker":"JAGX","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jaguar Health to present at Elite Ped-GI Congress 2025; updated investor deck furnished","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation scheduled April 24-26, 2025 in Abu Dhabi, UAR.","CEO will refer to an updated investor presentation furnished as Exhibit 99.1.","No specific financial or pipeline updates disclosed in the filing.","Exhibit 99.1 is an investor overview deck dated April 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1857652.2758620689,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2025-04-21T23:59:59+00:00|156318"}